



## Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021

April 29, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 29, 2021-- [Dicerna Pharmaceuticals, Inc.](#) (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2021 financial results after market close on Thursday, May 6, 2021.

Management will host a conference call at 4:30 p.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, [www.dicerna.com](http://www.dicerna.com). The webcast will also be archived on the Company's website.

The conference call can be accessed by dialing (855) 453-3834 or +1 (484) 756-4306 (international) and referencing conference ID 8088867 prior to the start of the call. A replay of the call will be available approximately two hours after the completion of the call and will remain available for seven days. To access the replay, please dial (855) 859-2056 or +1 (404) 537-3406 and refer to conference ID 8088867.

### About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna's GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, Dicerna has continued to innovate and is exploring new applications of its RNAi technology with GalXC-Plus, which expands on the functionality and application of our flagship liver-targeted GalXC technology, and has the potential to treat diseases across multiple therapeutic areas. In addition to our own pipeline of core discovery and clinical candidates, Dicerna has established collaborative relationships with some of the world's leading pharmaceutical companies, including Novo Nordisk A/S, Roche, Eli Lilly and Company, Alexion Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH and Alnylam Pharmaceuticals, Inc. Between Dicerna and our collaborative partners, we currently have more than 20 active discovery, preclinical or clinical programs focused on cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain. At Dicerna, our mission is to interfere – to silence genes, to fight disease, to restore health. For more information, please visit [www.dicerna.com](http://www.dicerna.com).

GalXC™ and GalXC-Plus™ are trademarks of Dicerna Pharmaceuticals, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210429005247/en/): <https://www.businesswire.com/news/home/20210429005247/en/>

#### Media:

Amy Trevvett  
+1 617-612-6253  
[atrevvett@dicerna.com](mailto:atrevvett@dicerna.com)

#### Investors:

[ir@dicerna.com](mailto:ir@dicerna.com)

Source: Dicerna Pharmaceuticals, Inc.